Drug
Lad603
Lad603: highest development phase Phase 2, developed by Almirall. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| LAD603 NCT07311564 | Phase 2 | Alopecia Areata |
| LAD603 NCT06200597 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Lad603 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.